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ess under CC BY-NC-Abstract Cell-penetrating peptides (CPPs) have been widely used to enhance the membrane transloca-
tion of various carriers for many years, but the non-speciﬁcity of CPPs seriously limits their utility in vivo.
In this study, cholesterol-anchored, reduction-sensitive PEG (ﬁrst synthesized by our laboratory) was
applied to develop a co-modiﬁed liposome with improved tumor targeting. Following optimization of the
formulation, the in vitro and in vivo properties of the co-modiﬁed liposome were evaluated. The co-
modiﬁed liposome had a much lower cellular uptake and tumor spheroid uptake, but a much higher tumor
accumulation compared to CPP-modiﬁed liposome, indicating the non-speciﬁc penetration of CPPs could
be attenuated by the outer PEG coating. With the addition of exogenous reducing agent, both the in vitro
and in vivo cellular uptake was markedly increased, demonstrating that the reduction-sensitive PEG
coating achieved a controllable detachment from the surface of liposomes and did not affect the
penetrating abilities of CPPs. The present results demonstrate that the combination of cholestervsitive
PEG and CPPs is an ideal alternative for the application of CPP-modiﬁed carriers in vivo.
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J. Tang et al.681. Introduction
Cancer is one of the world0s most deadly diseases and tumor-
targeted drug delivery systems are currently an important approach
for cancer treatment1–3. However, several barriers need to be
overcome in order to achieve ideal therapeutic efﬁcacy. Most
critical is the penetration of cytoplasmic and organelle membranes
by chemotherapeutic agents4. In many cases, cell-penetrating
peptides (CPPs) have been successfully used to deliver a large
variety of cargoes into individual cell organelles, resulting in
dramatically improved therapeutic outcomes5,6. Furthermore, some
CPPs promote lysosome escape7 or nuclear targeting of various
cargoes8.
However, CPPs penetrate cells without selectivity and also bind
plasma proteins easily, leading to recognition and clearance by the
reticuloendothelial system (RES)9. The latter property of CPP-
modiﬁed carriers accounts for their susceptibility to the so-called
“kinetic barriers”10, a signiﬁcant obstacle for drug delivery11.
Recently, smart stimuli-sensitive delivery systems have been
designed to endow CPP-containing formulations with selective
drug delivery and to increase circulation time in vivo without
weakening cell penetration12–14. In these delivery systems, the
function of CPPs can be selectively switched “on” and “off” by the
outer stimuli-sensitive PEG15. So far, a variety of stimuli-sensitive
PEG has been used in such delivery systems. Among these, the
reduction-sensitive PEG (based on disulﬁde linkage) is easy to
construct. The PEG detachment in this drug system can also be
precisely controlled by exogenous reducing agent16.
In our previous work, a cholesterol-anchored reduction-sensi-
tive PEG was successfully synthesized for the ﬁrst time17. In that
study, we developed a multifunctional liposome (CL-R8-LP)
incorporating two important properties. Octaarginines (R8, a
representative CPP) were used to penetrate the cytoplasmic
membrane barrier for liposomal drug delivery, and a detachable
coating from a cholesterol-anchored reduction-sensitive PEG was
applied to resist “kinetic barriers”. Presently, we have optimized
the formulation of CL-R8-LP by varying the concentrations of
PEG and R8, and characterized the in vitro cellular uptake and
tumor spheroid uptake of this formulation. In vivo and ex vivo
tumor imaging has further veriﬁed the tumor-targeting ability of
R8-modiﬁed liposomes containing the detachable PEG coating.2. Materials and methods
2.1. Materials
Egg phosphatidylcholine (EPC) and 1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine-N-(carboxyﬂuorescein) (CFPE) were purchased from
Avanti Polar Lipids, Inc. (Alabaster, USA). Cholesterol (CHO) and
cysteine (Cys) were purchased from Chengdu Kelong Chemical
Company (Chengdu, China). All the cholesterol anchored functional
materials were synthesized by our laboratory according to a previously
reported method17, including the cholesterol anchored reduction-
sensitive PEG (CHO-S-S-PEG5000), R8 modiﬁed PEG (CHO-
PEG2000-R8) and non-cleavable PEG2000 (CHO-mPEG2000). Agarose
LMP was purchased from Invitrogen (Carlsbad, CA). 1,10-Dioctadecyl-
3,3,30,30-tetramethylindodicarbocyanine 4-chlorobenzenesulfonate salt
(DID) was obtained from Biotium (Hayward, CA). Other chemicals
and reagents were of analytical grade.
Male BALB/c mice weighing 20–25 g were purchased from
Experiment Animal Center of Sichuan University (China). All theanimal experiments adhered to the principles of care and use of
laboratory animals and were approved by the Experiment Animal
Administrative Committee of Sichuan University.2.2. Preparation of liposomes
Liposomes modiﬁed with different cholesterol anchored functional
lipids were prepared by the lipid ﬁlm hydration-ultrasound
method18. Brieﬂy, the basic composition was EPC/CHO¼65:35,
and the percentage of cholesterol decreased with the addition of
various cholesterol anchored functional lipids. All the lipids were
dissolved in chloroform and a lipid ﬁlm was obtained after the
solvent was evaporated by rotary evaporator at 37 1C for 15 min.
The lipid ﬁlm was then hydrated in PBS (pH 7.4) at 37 1C for 1 h,
and further sonicated with a probe sonicator at 80 W for 75 s. To
prepare CFPE-labeled and DID-loaded liposomes, CFPE and DID
ﬂuorescence probe were dissolved in chloroform at the beginning,
following operations were the same as described above. The total
lipid concentration of liposomes was at 3 mmol/L.
2.3. Characterization of liposomes
The size and zeta-potential of liposomes were detected by Malvern
Zetasizer Nano ZS90 (Malvern Instruments Ltd., UK). Prior to
measurement, 100 μL of the sample was diluted to 1 mL using the
same buffer.
2.4. Cell culture
C26 cells were grown in RPMI-1640 medium (GIBCO) containing
10% FBS, 100 μg/mL streptomycin, and 100 U/mL penicillin. The
cells were maintained at 37 1C in a humidiﬁed incubator with 5%
CO2.
2.5. Cellular uptake study
For the cellular uptake study, about 1 105 cells per well were
seeded in 6-well plates and cultured for 24 h. The CFPE-labeled
liposomes were added to the plates with a total lipid concentration
of 0.3 mmol/L. After incubation in the absence or presence of Cys
(10 mmol/L) which was used to provide a reducing environment for
the cleavage of reduction-sensitive PEG for 4 h at 37 1C16,19, the
cells were washed three times with cold PBS (pH 7.4) and ﬁxed
using 4% paraformaldehyde for 30 min. After that, 1 mL of 2 μg/
mL DAPI was added and incubated for 5 min. The cellular uptake
of various CFPE-labeled liposomes was then qualitatively observed
via confocal laser scanning microscope (CLSM) (Leica, Germany).
For quantitative uptake measurements, cells were incubated with
CFPE-labeled liposomes for 4 h, detached by 0.25% trypsin,
washed and resuspended in 0.5 mL PBS, and analyzed by ﬂow
cytometry.2.6. Tumor spheroid uptake
The three-dimensional tumor spheroids of C26 were established as
described previously20,21 with some modiﬁcation. Cells (2 103
per well) were plated onto a 96-well plate pre-coated with 40 μL
2% low melting point agarose. Several days later, spheroids (300–
400 μm diameters) were treated with 0.3 mmol/L CFPE-labeled
Detachable coating of cholesterol-anchored PEG 69R8-LP, PEG-LP and CL-R8-LP in the presence or absence of Cys
(10 mmol/L) for 4 h. They were rinsed with PBS, followed by
ﬁxation of 4% paraformaldehyde for 0.5 h, and the spheroid
ﬂuorescent intensities captured by CLSM.2.7. In vivo and ex vivo tumor imaging
In vivo and ex vivo ﬂuorescence imaging experiments were
performed using the Bio-Real in vivo imaging system (Quick
View 3000, Bio-Real, AUSTRIA). The tumor-bearing mice were
established by subcutaneous inoculation of 1 106 C26 cells in
the left ﬂank of BALB/c mice. The C26 tumor-bearing mice were
randomly assigned into different groups with three mice each
when the tumor diameters reached about 10 mm, and injected
intravenously with DID-loaded liposomes at a dose of 500 μg
DID/kg. Twenty-four hour after injection, mice were imaged with
Bio-Real in vivo imaging system, and immediately euthanized with
cervical dislocation. Hearts, livers, spleens, lungs, kidneys and
tumors were collected. Organs were imaged with Bio-Real in vivo
imaging system. DID ﬂuorescence (excitation 644 nm, emission
665 nm) was monitored to localize the liposomes. For the
qualitative evaluation of cellular uptake of the DID-loaded
liposome in tumors, at 24 h post-injection, Cys (120 mg/kg) or
PBS was injected. Tumors were excised and frozen sectioned 4 h
later. Nuclei were stained with DAPI and ﬂuorescent intensity of
slices was observed via CLSM.2.8. Statistics
Results were expressed as a mean7standard deviation (SD). One-
way ANOVA was used to compare differences, signiﬁcance was
deﬁned as a P value of o0.001.Figure 1 Formulation optimization of liposomes modiﬁed with various
different liposomes by C26 in the absence (A) and presence (B) of Cys.
represented the mean7SD (n¼3).3. Results
3.1. Optimization of liposomal formulations
To develop the proposed co-modiﬁed liposomes, it should be
noted that R8 were not functional in the presence of reduction-
sensitive PEG. Then we evaluated the cellular uptake of different
liposomes with various concentrations of CHO-S-S-PEG5000 and
R8. Cellular uptake of liposomes in the absence of Cys was
signiﬁcantly decreased with increasing the concentrations of CHO-
S-S-PEG5000 (Fig. 1A), which was correlated with their zeta-
potentials (Fig. 1C). The addition of Cys produced a remarkable
increase in the cellular uptake of liposomes modiﬁed with 0.8, 2,
5 mol% of R8 (Fig. 1B). The uptake and zeta potential of the
0.8 mol% R8þ10 mol% CHO-S-S-PEG5000 liposomal formulation
was nearly the same as the control liposomal formulation (0 mol%
R8þ10 mol% CHO-S-S-PEG5000), indicating this to be the
optimal formulation, since R8 on the liposomal surface was
complete masked by the aqueous layer of the PEG moiety.3.2. Characterization of liposomes
After the optimal formulation was selected, the average diameter
and zeta-potential of the CL-R8-LP and the control liposomes
were determined (Table 1). Liposome sizes (diameter) were mainly
around 90 nm. The zeta potential of R8-LP was strongly positive,
whereas the CL-R8-LP and PEG-LP was nearly neutral.3.3. Qualitative evaluation of cellular uptake in vitro
The cellular uptake of different liposomes (see Table 1) by C26
cells was investigated by CLSM. As shown in Fig. 2, R8-LPconcentrations of CHO-S-S-PEG5000 and R8. The cellular uptake of
(C) The zeta potentials of different co-modiﬁed liposomes. The data
Table 1 Composition of different liposomes (mol%) and their characteristics.
Abbreviation Corresponding composition Characteristic
EPC (%) CHO (%) Cholesterol anchored functional lipids Size (nm) PDI Zeta (mV)
R8-LP 65.0 34.2 0.8% CHO-PEG2000-R8 107.474.1 0.25070.019 8.9071.63
CL-R8-LP 65.0 24.2 0.8% CHO-PEG2000-R8/10% CHO-S-S-PEG5000 89.472.6 0.10270.011 1.1770.38
PEG-LP 65.0 32.0 3% CHO-PEG2000 96.375.4 0.14870.021 2.4571.55
Data are mean7SD (n¼3).
Figure 2 CLSM images of C26 cells incubated with different CFPE-labeled liposomes at 37 1C for 4 h. Left to right columns show: bright ﬁeld
(I), DAPI blue ﬂuorescent nuclei (II), FITC-labeled green ﬂuorescent liposomes (III), and merged ﬁelds (IV).
J. Tang et al.70resulted in stronger ﬂuorescence signals inside cells. Following the
addition of 10 mol% of CHO-S-S-PEG5000, the ﬂuorescence
signals of CL-R8-LP were almost invisible, indicating the function
of R8 could be completely masked by CHO-S-S-PEG5000. In the
presence of Cys, however, the ﬂuorescence intensity of CL-R8-LP
was the same as R8-LP, suggesting CHO-S-S-PEG5000 was
detached from the surface of liposome in the reducing environ-
ment. The cellular uptake of PEG-LP without the modiﬁcation of
R8 was minimal.Figure 3 Fluorescence intensity of C26 cells measured by ﬂow
cytometer after incubated with different CFPE-labeled liposomes at
37 1C for 4 h. Data represent the mean7SD (n¼3). ***Po0.001;
N.S.¼no signiﬁcant difference.3.4. Quantitative evaluation of cellular uptake in vitro
The quantitative results of cellular uptake were consistent with the
results of ﬂuorescence imaging. As shown in Fig. 3, the uptake
amount of CL-R8-LP in the presence of Cys was 21.6 and 66.5
times higher than that of CL-R8-LP in the absence of Cys and
Figure 4 Representative CLSM images of C26 tumor spheroids incubated with different CFPE-labeled liposomes at 37 1C for 4 h.
Figure 5 The representative in vivo (A) and ex vivo (B) images of C26 tumor-bearing mice 24 h after injection of DID-loaded liposomes.
(C) The CLSM images of tumor frozen sections from C26 tumor-bearing mice receiving different DID-loaded liposomes.
Detachable coating of cholesterol-anchored PEG 71PEG-LP respectively, and was comparable to the cellular uptake of
R8-LP.3.5. Evaluation of tumor spheroid uptake in vitro
The three-dimensional tumor spheroid models are commonly used
as an ideal in vitro platform mimicking solid tumors to predict
delivery efﬁciency and mechanism22. To further evaluate the
delivery characteristics of liposomes, tumor spheroid uptake
experiments were carried out. At 4 h, little ﬂuorescence was
detected within tumor spheroids from PEG-LP and CL-R8-LP
(in the absence of Cys). In contrast, R8-LP and CL-R8-LP (in the
presence of Cys) treated tumor spheroids demonstrated much
greater ﬂuorescence (Fig. 4), indicating that the modiﬁcation and
exposure of R8 on the liposomal surface could not only increasethe uptake by C26 cells but also facilitate the delivery of liposomes
into tumor spheroids.3.6. In vivo and ex vivo tumor imaging
To estimate the in vivo liposomal delivery to tumors, whole body
optical imaging and ex vivo organ imaging were taken using the
Bio-Real in vivo imaging system. Fig. 5A shows that 24 h after
injection of different liposomes, ﬂuorescence intensity in the tumors
of CL-R8-LP-treated mice were signiﬁcantly higher than that of
R8-treated mice, and even slightly stronger than that of PEG-LP-
treated mice. These ﬁndings were consistent with the results of
ex vivo organ imaging at 24 h (Fig. 5B). In addition, R8-LP was
mostly distributed in liver, spleen and lung, whereas CL-R8-LP and
PEG-LP distributions in these organs were decreased signiﬁcantly
J. Tang et al.72(Fig. 5B). To further explore the delivery characteristics of CL-R8-
LP and PEG-LP liposomes into cells after the sufﬁcient tumor
accumulation, tumor sections from C26 tumor-bearing mice receiv-
ing different liposomes were observed by CLSM. Fluorescence
intensities in the tumor sections of CL-R8-LP (with Cys) treated
mice were much higher than those of PEG-Lip and CL-R8-LP
(without Cys) treated mice.4. Discussion
For many years, CPPs have been widely applied in the drug
delivery system for their excellent membrane-penetrating ability23.
But the apparent ability of CPPs to penetrate virtually all cell types
represents a major weakness for their in vivo use. To address this
problem in the present study, the cholesterol anchored reduction-
sensitive PEG synthesized by our laboratory was incorporated into
CPP-modiﬁed liposomes. Compared with some other stimuli-
sensitive materials, the cholesterol anchored reduction-sensitive
PEG based on disulﬁde linkage has many advantages. First of all,
cholesterol, serving as a neutral anchor, is inexpensive and more
chemically stable than the most commonly used DSPE anchor24.
Secondly, the disulﬁde linkage is easy to construct and is easily
reduced16. Finally, the detachment of reduction-sensitive PEG is
more controllable than pH-sensitive, MMP-sensitive or esterase-
sensitive forms of PEG. Unlike the latter, which depend entirely
on the speciﬁc physiological conditions, the former can be
precisely cleaved by the exogenous reducing agent cysteine19,25.
The objectives of the addition of sensitive PEG were to mask
the nonspeciﬁc binding of CPPs in plasma, to increase the
circulation time of carriers, and to enhance passive tumor target-
ing. Firstly, to maximize the masking effect of reduction-sensitive
PEG on R8, we optimized the concentrations of CHO-S-S-
PEG5000 and R8, and the results (Fig. 1) clearly showed that the
higher concentration of CHO-S-S-PEG5000, the better the masking
effect on R8. However, too high of a concentration of outer PEG
layer would reduce the stability of the lipid bilayer26. In our lab,
liposomes become unstable (indicated by large increases in PDI)
when the concentrations of CHO-S-S-PEG5000 exceed 10% (data
not shown). By the modiﬁcation of 10 mol% CHO-S-S-PEG5000,
the positive charge of R8 was completely shielded, and the zeta
potential of co-modiﬁed liposome (CL-R8-LP) became neutral
(Table 1), alleviating the electrostatic interaction between the
positively charged CPPs and the negatively charged plasma
membrane. Accordingly, the interaction between the positively
charged CPPs and the negatively charged cell membrane wea-
kened, and the uptake of CL-R8-LP by cells and tumor spheroids
was much lower than that of R8-LP (Figs. 2–4). All these results
suggest that the non-speciﬁcity of R8 shielded the outer PEG
layer. And compared to the conventional non-cleavable PEG, the
reduction-sensitive PEG modiﬁcation couldn0t bring about a steric
hindrance that prevents carriers from efﬁcient interaction with
cellular membranes and/or endosomal membranes. This contra-
dictory effect of PEGylation has been usually called the “PEG
dilemma”27,28. As shown as Fig. 3, in the presence of Cys, the
cellular uptake of CL-R8-LP was comparable to that of R8-LP,
indicating the outer reduction-sensitive PEG layer was efﬁciently
detached from the surface of liposomes, consistent with the
qualitative results of cell uptake (Fig. 2) and tumor spheroid
uptake (Fig. 4).
The results of in vivo and ex vivo tumor imaging (Fig. 5A and
B) showed that R8-LP which lacks the PEG coating mainlydistributed in RES related organs (liver, spleen and lung). Thus,
CL-R8-LP can undergo a prolonged circulation time in vivo and
beneﬁt from the EPR effect, thereby achieving efﬁcient accumula-
tion within the tumor. It is worth noting that the tumor distribu-
tions of CL-R8-LP were also stronger than the conventional long
circulation liposome PEG-LP. This can be explained by the
conformational changes of outer PEG layer. Previous studies
demonstrated that when the concentration of the outer PEG layer
is relatively low (o4%), PEG adopts a “mushroom” conforma-
tion. At increasingly higher concentrations, the “transition” and
“brush” (48%) conformations emerge. The brush conformation
has been linked to a “stealth” of carriers26,29. These results
demonstrate that the modiﬁcation with a relatively high concen-
tration of reduction-sensitive PEG (10%) can help carriers to
surmount efﬁciently the in vivo “kinetic barriers”. Furthermore,
after the sufﬁcient tumor accumulations were achieved, this PEG
coating will not affect the penetrating ability of liposomes into
cells when the proper reducing environment is provided (Fig. 5C).5. Conclusions
A cholesterol anchored reduction-sensitive PEG was applied here
to help R8 modiﬁed liposomes achieve tumor targeted delivery
in vivo. The combination of reduction-sensitive PEG and CPPs
could overcome in vivo “kinetic barriers” and the cytoplasmic
membrane barrier under the control of Cys. This new liposome
formulation improves the non-speciﬁcity of CPPs and enhances
the tumor targeted drug delivery of CPP-modiﬁed carriers.Acknowledgments
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